Cobas 8000 Core Unit
Payments companies reported to CMS as associated with Cobas 8000 Core Unit. "Associated with" is CMS's wording: it links a payment to a product without saying the money was spent on it.
By year
Payments reported as associated with Cobas 8000 Core Unit, per program year, as reported to CMS.
Who makes it
Specialties most often involved
Where the associated payments went, by the receiving clinician's specialty.
Clinicians most associated with Cobas 8000 Core Unit
These are the largest totals companies reported as associated with Cobas 8000 Core Unit. They are typically speaking or consulting arrangements, which companies must report by law; appearing here is not evidence of anything improper.
| Clinician | Location | Specialty | Associated payments (2023-2025) |
|---|---|---|---|
| David Pride | San Diego, CA | Infectious Disease | $4,280.00 |
| Ambarish Pandey | Dallas, TX | Cardiovascular Disease | $2,885.00 |
| Payal Patel | Ann Arbor, MI | Infectious Disease | $2,568.00 |
| James Januzzi | Boston, MA | Cardiovascular Disease | $2,465.00 |
| Javed Butler | Jackson, MS | Advanced Heart Failure and Transplant Cardiology | $2,465.00 |
| Stephen Greene | Durham, NC | Advanced Heart Failure and Transplant Cardiology | $2,465.00 |
| Suzanne Crumley | Saint Louis, MO | Anatomic Pathology & Clinical Pathology | $109.84 |
| Jean Marie Lopategui | West Hollywood, CA | $39.12 | |
| Valentin Robu | Greenville, SC | Anatomic Pathology & Clinical Pathology | $36.92 |
| Lakshmy Parameswaran | Springfield, OH | Anatomic Pathology & Clinical Pathology | $36.92 |
Prescribed Cobas 8000 Core Unit?
See what its makers reported for your doctor. Two steps, private, no account.
Source: CMS Open Payments, program years 2019-2025, as reported to CMS by drug and device makers (published June 30, 2026). Drug and device detail covers 2023-2025.